#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5. Fibrin Handling for Bioactive Compounds Delivery
1-1	0-2	5.	_	_	_	_
1-2	3-9	Fibrin	substance|abstract[2]	new|new[2]	coref	2-3
1-3	10-18	Handling	abstract[2]	new[2]	_	_
1-4	19-22	for	abstract[2]	new[2]	_	_
1-5	23-32	Bioactive	abstract[2]|abstract[3]|abstract[4]	new[2]|new[3]|new[4]	coref	18-11[0_4]
1-6	33-42	Compounds	abstract[2]|abstract[3]|abstract[4]	new[2]|new[3]|new[4]	_	_
1-7	43-51	Delivery	abstract[2]|abstract[4]	new[2]|new[4]	_	_

#Text=5.1. Tuning Fibrin Intrinsic Characteristics
2-1	52-56	5.1.	_	_	_	_
2-2	57-63	Tuning	_	_	_	_
2-3	64-70	Fibrin	substance|abstract[6]	giv|new[6]	coref	3-20
2-4	71-80	Intrinsic	abstract[6]	new[6]	_	_
2-5	81-96	Characteristics	abstract[6]	new[6]	_	_

#Text=Bioactive compounds including growth factors , cytokines , drugs , and nucleic acids can be easily entrapped in the fibrin matrix by mixing them with fibrinogen or thrombin .
3-1	97-106	Bioactive	substance[7]	new[7]	coref	6-8[42_7]
3-2	107-116	compounds	substance[7]	new[7]	_	_
3-3	117-126	including	substance[7]	new[7]	_	_
3-4	127-133	growth	substance[7]|abstract|abstract[9]|abstract[10]	new[7]|new|new[9]|new[10]	ana|coref|coref	3-24[0_10]|19-12|19-12[133_9]
3-5	134-141	factors	substance[7]|abstract[9]|abstract[10]	new[7]|new[9]|new[10]	_	_
3-6	142-143	,	substance[7]|abstract[10]	new[7]|new[10]	_	_
3-7	144-153	cytokines	substance[7]|abstract[10]|substance	new[7]|new[10]|new	_	_
3-8	154-155	,	substance[7]|abstract[10]	new[7]|new[10]	_	_
3-9	156-161	drugs	substance[7]|abstract[10]|substance	new[7]|new[10]|new	_	_
3-10	162-163	,	substance[7]|abstract[10]	new[7]|new[10]	_	_
3-11	164-167	and	substance[7]|abstract[10]	new[7]|new[10]	_	_
3-12	168-175	nucleic	substance[7]|abstract[10]|substance[13]	new[7]|new[10]|new[13]	_	_
3-13	176-181	acids	substance[7]|abstract[10]|substance[13]	new[7]|new[10]|new[13]	_	_
3-14	182-185	can	_	_	_	_
3-15	186-188	be	_	_	_	_
3-16	189-195	easily	_	_	_	_
3-17	196-205	entrapped	_	_	_	_
3-18	206-208	in	_	_	_	_
3-19	209-212	the	substance[15]	new[15]	coref	4-4[21_15]
3-20	213-219	fibrin	substance|substance[15]	giv|new[15]	coref	4-4
3-21	220-226	matrix	substance[15]	new[15]	_	_
3-22	227-229	by	_	_	_	_
3-23	230-236	mixing	_	_	_	_
3-24	237-241	them	abstract	giv	_	_
3-25	242-246	with	_	_	_	_
3-26	247-257	fibrinogen	substance|abstract[18]	new|new[18]	coref|coref	4-14|5-4[28_18]
3-27	258-260	or	abstract[18]	new[18]	_	_
3-28	261-269	thrombin	abstract[18]|place	new[18]|new	coref	4-12
3-29	270-271	.	_	_	_	_

#Text=In general , fibrin matrix remains porous regardless the conditions and/or thrombin and fibrinogen ratios .
4-1	272-274	In	_	_	_	_
4-2	275-282	general	_	_	_	_
4-3	283-284	,	_	_	_	_
4-4	285-291	fibrin	substance|substance[21]	giv|giv[21]	coref|coref	5-13|7-35[0_21]
4-5	292-298	matrix	substance[21]	giv[21]	_	_
4-6	299-306	remains	_	_	_	_
4-7	307-313	porous	_	_	_	_
4-8	314-324	regardless	abstract[22]	new[22]	_	_
4-9	325-328	the	abstract[22]	new[22]	_	_
4-10	329-339	conditions	abstract[22]	new[22]	_	_
4-11	340-346	and/or	_	_	_	_
4-12	347-355	thrombin	place|abstract[24]|abstract[26]	giv|new[24]|new[26]	coref|coref	5-6|10-10[70_24]
4-13	356-359	and	abstract[24]|abstract[26]	new[24]|new[26]	_	_
4-14	360-370	fibrinogen	abstract[24]|substance|abstract[26]	new[24]|giv|new[26]	coref	5-4
4-15	371-377	ratios	abstract[26]	new[26]	_	_
4-16	378-379	.	_	_	_	_

#Text=However , increasing fibrinogen and/or thrombin concentrations densifies the structure of a fibrin gel and reduces its degradation rate , thus slowing down the diffusion of loaded molecules ( e.g. , FGF ) .
5-1	380-387	However	_	_	_	_
5-2	388-389	,	_	_	_	_
5-3	390-400	increasing	animal[30]	new[30]	_	_
5-4	401-411	fibrinogen	substance|abstract[28]|animal[30]	giv|giv[28]|new[30]	_	_
5-5	412-418	and/or	abstract[28]|animal[30]	giv[28]|new[30]	_	_
5-6	419-427	thrombin	abstract[28]|place|animal[30]	giv[28]|giv|new[30]	coref	10-10
5-7	428-442	concentrations	animal[30]	new[30]	_	_
5-8	443-452	densifies	_	_	_	_
5-9	453-456	the	abstract[31]	new[31]	ana	5-17[0_31]
5-10	457-466	structure	abstract[31]	new[31]	_	_
5-11	467-469	of	abstract[31]	new[31]	_	_
5-12	470-471	a	abstract[31]|object[33]	new[31]|new[33]	coref	12-20[93_33]
5-13	472-478	fibrin	abstract[31]|substance|object[33]	new[31]|giv|new[33]	coref	10-3
5-14	479-482	gel	abstract[31]|object[33]	new[31]|new[33]	_	_
5-15	483-486	and	_	_	_	_
5-16	487-494	reduces	_	_	_	_
5-17	495-498	its	abstract|abstract[36]	giv|new[36]	_	_
5-18	499-510	degradation	abstract|abstract[36]	new|new[36]	coref	9-3[62_0]
5-19	511-515	rate	abstract[36]	new[36]	_	_
5-20	516-517	,	_	_	_	_
5-21	518-522	thus	_	_	_	_
5-22	523-530	slowing	_	_	_	_
5-23	531-535	down	_	_	_	_
5-24	536-539	the	event[37]	new[37]	ana	7-26[51_37]
5-25	540-549	diffusion	event[37]	new[37]	_	_
5-26	550-552	of	event[37]	new[37]	_	_
5-27	553-559	loaded	event[37]|object[38]	new[37]|new[38]	coref	7-4[49_38]
5-28	560-569	molecules	event[37]|object[38]	new[37]|new[38]	_	_
5-29	570-571	(	_	_	_	_
5-30	572-576	e.g.	abstract[39]	new[39]	coref	32-6[0_39]
5-31	577-578	,	abstract[39]	new[39]	_	_
5-32	579-582	FGF	abstract[39]	new[39]	_	_
5-33	583-584	)	_	_	_	_
5-34	585-586	.	_	_	_	_

#Text=In addition , the release profile of active compounds is affected by their physicochemical properties including partition coefficient , size and functional groups .
6-1	587-589	In	_	_	_	_
6-2	590-598	addition	_	_	_	_
6-3	599-600	,	_	_	_	_
6-4	601-604	the	abstract[41]	new[41]	_	_
6-5	605-612	release	event|abstract[41]	new|new[41]	coref	10-14[72_0]
6-6	613-620	profile	abstract[41]	new[41]	_	_
6-7	621-623	of	abstract[41]	new[41]	_	_
6-8	624-630	active	abstract[41]|substance[42]	new[41]|giv[42]	ana	6-13[0_42]
6-9	631-640	compounds	abstract[41]|substance[42]	new[41]|giv[42]	_	_
6-10	641-643	is	_	_	_	_
6-11	644-652	affected	_	_	_	_
6-12	653-655	by	_	_	_	_
6-13	656-661	their	substance|abstract[44]	giv|new[44]	coref	8-3[59_0]
6-14	662-677	physicochemical	abstract[44]	new[44]	_	_
6-15	678-688	properties	abstract[44]	new[44]	_	_
6-16	689-698	including	abstract[44]	new[44]	_	_
6-17	699-708	partition	abstract[44]|event|abstract[46]	new[44]|new|new[46]	_	_
6-18	709-720	coefficient	abstract[44]|abstract[46]	new[44]|new[46]	_	_
6-19	721-722	,	abstract[44]	new[44]	_	_
6-20	723-727	size	abstract[44]|abstract	new[44]|new	_	_
6-21	728-731	and	abstract[44]	new[44]	_	_
6-22	732-742	functional	abstract[44]|person[48]	new[44]|new[48]	coref	20-7[140_48]
6-23	743-749	groups	abstract[44]|person[48]	new[44]|new[48]	_	_
6-24	750-751	.	_	_	_	_

#Text=For example , hydrophilic molecules readily leach out ( e.g. , erythromycin , mitomycin C , fluorouracil etc. ) , while hydrophobic molecules , or those which display a strong chemical affinity for the matrix components , are released more gradually ( e.g. , streptomycin , sulfamethoxazole-trimethoprim , cefazolin , enocitabine etc. ) .
7-1	752-755	For	_	_	_	_
7-2	756-763	example	_	_	_	_
7-3	764-765	,	_	_	_	_
7-4	766-777	hydrophilic	object[49]	giv[49]	_	_
7-5	778-787	molecules	object[49]	giv[49]	_	_
7-6	788-795	readily	_	_	_	_
7-7	796-801	leach	_	_	_	_
7-8	802-805	out	_	_	_	_
7-9	806-807	(	_	_	_	_
7-10	808-812	e.g.	_	_	_	_
7-11	813-814	,	_	_	_	_
7-12	815-827	erythromycin	_	_	_	_
7-13	828-829	,	_	_	_	_
7-14	830-839	mitomycin	_	_	_	_
7-15	840-841	C	_	_	_	_
7-16	842-843	,	_	_	_	_
7-17	844-856	fluorouracil	_	_	_	_
7-18	857-861	etc.	_	_	_	_
7-19	862-863	)	_	_	_	_
7-20	864-865	,	_	_	_	_
7-21	866-871	while	_	_	_	_
7-22	872-883	hydrophobic	object[50]	new[50]	coref	21-12[148_50]
7-23	884-893	molecules	object[50]	new[50]	_	_
7-24	894-895	,	_	_	_	_
7-25	896-898	or	_	_	_	_
7-26	899-904	those	event[51]	giv[51]	coref	9-13[0_51]
7-27	905-910	which	event[51]	giv[51]	_	_
7-28	911-918	display	event[51]	giv[51]	_	_
7-29	919-920	a	event[51]|abstract[52]	giv[51]|new[52]	coref	19-7[130_52]
7-30	921-927	strong	event[51]|abstract[52]	giv[51]|new[52]	_	_
7-31	928-936	chemical	event[51]|abstract[52]	giv[51]|new[52]	_	_
7-32	937-945	affinity	event[51]|abstract[52]	giv[51]|new[52]	_	_
7-33	946-949	for	event[51]|abstract[52]	giv[51]|new[52]	_	_
7-34	950-953	the	event[51]|abstract[52]|object[54]	giv[51]|new[52]|new[54]	_	_
7-35	954-960	matrix	event[51]|abstract[52]|substance|object[54]	giv[51]|new[52]|giv|new[54]	coref	8-21[61_0]
7-36	961-971	components	event[51]|abstract[52]|object[54]	giv[51]|new[52]|new[54]	_	_
7-37	972-973	,	_	_	_	_
7-38	974-977	are	_	_	_	_
7-39	978-986	released	_	_	_	_
7-40	987-991	more	_	_	_	_
7-41	992-1001	gradually	_	_	_	_
7-42	1002-1003	(	_	_	_	_
7-43	1004-1008	e.g.	plant[55]	new[55]	_	_
7-44	1009-1010	,	plant[55]	new[55]	_	_
7-45	1011-1023	streptomycin	plant[55]	new[55]	_	_
7-46	1024-1025	,	_	_	_	_
7-47	1026-1055	sulfamethoxazole-trimethoprim	substance	new	_	_
7-48	1056-1057	,	_	_	_	_
7-49	1058-1067	cefazolin	substance	new	_	_
7-50	1068-1069	,	_	_	_	_
7-51	1070-1081	enocitabine	substance	new	_	_
7-52	1082-1086	etc.	_	_	_	_
7-53	1087-1088	)	_	_	_	_
7-54	1089-1090	.	_	_	_	_

#Text=Thus , some compounds need to be modified chemically to become more hydrophobic , resulting in a prolonged retention within the matrix .
8-1	1091-1095	Thus	_	_	_	_
8-2	1096-1097	,	_	_	_	_
8-3	1098-1102	some	substance[59]	giv[59]	coref	10-17[73_59]
8-4	1103-1112	compounds	substance[59]	giv[59]	_	_
8-5	1113-1117	need	_	_	_	_
8-6	1118-1120	to	_	_	_	_
8-7	1121-1123	be	_	_	_	_
8-8	1124-1132	modified	_	_	_	_
8-9	1133-1143	chemically	_	_	_	_
8-10	1144-1146	to	_	_	_	_
8-11	1147-1153	become	_	_	_	_
8-12	1154-1158	more	_	_	_	_
8-13	1159-1170	hydrophobic	_	_	_	_
8-14	1171-1172	,	_	_	_	_
8-15	1173-1182	resulting	_	_	_	_
8-16	1183-1185	in	_	_	_	_
8-17	1186-1187	a	event[60]	new[60]	_	_
8-18	1188-1197	prolonged	event[60]	new[60]	_	_
8-19	1198-1207	retention	event[60]	new[60]	_	_
8-20	1208-1214	within	event[60]	new[60]	_	_
8-21	1215-1218	the	event[60]|substance[61]	new[60]|giv[61]	coref	10-4[0_61]
8-22	1219-1225	matrix	event[60]|substance[61]	new[60]|giv[61]	_	_
8-23	1226-1227	.	_	_	_	_

#Text=Conversely , a proteolytic degradation may be required to speed up the diffusion process .
9-1	1228-1238	Conversely	_	_	_	_
9-2	1239-1240	,	_	_	_	_
9-3	1241-1242	a	abstract[62]	giv[62]	coref	15-16[117_62]
9-4	1243-1254	proteolytic	abstract[62]	giv[62]	_	_
9-5	1255-1266	degradation	abstract[62]	giv[62]	_	_
9-6	1267-1270	may	_	_	_	_
9-7	1271-1273	be	_	_	_	_
9-8	1274-1282	required	_	_	_	_
9-9	1283-1285	to	_	_	_	_
9-10	1286-1291	speed	_	_	_	_
9-11	1292-1294	up	_	_	_	_
9-12	1295-1298	the	event[64]	new[64]	_	_
9-13	1299-1308	diffusion	event|event[64]	giv|new[64]	_	_
9-14	1309-1316	process	event[64]	new[64]	_	_
9-15	1317-1318	.	_	_	_	_

#Text=Lastly , fibrin matrix proteolysis through the action of thrombin or plasmin induces the release of entrapped compounds .
10-1	1319-1325	Lastly	_	_	_	_
10-2	1326-1327	,	_	_	_	_
10-3	1328-1334	fibrin	substance|abstract[67]	giv|new[67]	coref|coref	11-14[0_67]|12-20
10-4	1335-1341	matrix	substance|abstract[67]	giv|new[67]	coref	11-8[75_0]
10-5	1342-1353	proteolysis	abstract[67]	new[67]	_	_
10-6	1354-1361	through	abstract[67]	new[67]	_	_
10-7	1362-1365	the	abstract[67]|event[68]	new[67]|new[68]	_	_
10-8	1366-1372	action	abstract[67]|event[68]	new[67]|new[68]	_	_
10-9	1373-1375	of	abstract[67]|event[68]	new[67]|new[68]	_	_
10-10	1376-1384	thrombin	abstract[67]|event[68]|place|abstract[70]	new[67]|new[68]|giv|giv[70]	_	_
10-11	1385-1387	or	abstract[67]|event[68]|abstract[70]	new[67]|new[68]|giv[70]	_	_
10-12	1388-1395	plasmin	abstract[67]|event[68]|abstract[70]|substance	new[67]|new[68]|giv[70]|new	coref	14-5
10-13	1396-1403	induces	_	_	_	_
10-14	1404-1407	the	event[72]	giv[72]	_	_
10-15	1408-1415	release	event[72]	giv[72]	_	_
10-16	1416-1418	of	event[72]	giv[72]	_	_
10-17	1419-1428	entrapped	event[72]|substance[73]	giv[72]|giv[73]	coref	19-23[136_73]
10-18	1429-1438	compounds	event[72]|substance[73]	giv[72]|giv[73]	_	_
10-19	1439-1440	.	_	_	_	_

#Text=In order to restrict this breakdown of the matrix , the co-entrapment of proteolysis inhibitors ( aprotinin , matrix metalloproteinases inhibitors such as galardin ) was investigated .
11-1	1441-1443	In	_	_	_	_
11-2	1444-1449	order	_	_	_	_
11-3	1450-1452	to	_	_	_	_
11-4	1453-1461	restrict	_	_	_	_
11-5	1462-1466	this	event[74]	new[74]	coref	12-20[94_74]
11-6	1467-1476	breakdown	event[74]	new[74]	_	_
11-7	1477-1479	of	event[74]	new[74]	_	_
11-8	1480-1483	the	event[74]|substance[75]	new[74]|giv[75]	coref	11-19[0_75]
11-9	1484-1490	matrix	event[74]|substance[75]	new[74]|giv[75]	_	_
11-10	1491-1492	,	_	_	_	_
11-11	1493-1496	the	abstract[76]	new[76]	_	_
11-12	1497-1510	co-entrapment	abstract[76]	new[76]	_	_
11-13	1511-1513	of	abstract[76]	new[76]	_	_
11-14	1514-1525	proteolysis	abstract[76]|abstract|abstract[78]	new[76]|giv|new[78]	appos	11-17[80_78]
11-15	1526-1536	inhibitors	abstract[76]|abstract[78]	new[76]|new[78]	_	_
11-16	1537-1538	(	_	_	_	_
11-17	1539-1548	aprotinin	person|abstract[80]	new|giv[80]	appos|coref	11-19[83_80]|15-6
11-18	1549-1550	,	abstract[80]	giv[80]	_	_
11-19	1551-1557	matrix	abstract[80]|substance|abstract[83]	giv[80]|giv|giv[83]	ana|coref	12-6[0_83]|17-9[121_0]
11-20	1558-1576	metalloproteinases	abstract[80]|substance|abstract[83]	giv[80]|new|giv[83]	coref	13-4
11-21	1577-1587	inhibitors	abstract[80]|abstract[83]	giv[80]|giv[83]	_	_
11-22	1588-1592	such	abstract[80]|abstract[83]	giv[80]|giv[83]	_	_
11-23	1593-1595	as	abstract[80]|abstract[83]	giv[80]|giv[83]	_	_
11-24	1596-1604	galardin	abstract[80]|abstract[83]|plant	giv[80]|giv[83]|new	coref	15-8[113_0]
11-25	1605-1606	)	_	_	_	_
11-26	1607-1610	was	_	_	_	_
11-27	1611-1623	investigated	_	_	_	_
11-28	1624-1625	.	_	_	_	_

#Text=Ahmed et al. identified in their model ( i.e. , chondroprogenitor clonal cell line ) the enzymes responsible for fibrin gel breakdown .
12-1	1626-1631	Ahmed	person	new	_	_
12-2	1632-1634	et	_	_	_	_
12-3	1635-1638	al.	_	_	_	_
12-4	1639-1649	identified	_	_	_	_
12-5	1650-1652	in	_	_	_	_
12-6	1653-1658	their	abstract|abstract[87]	giv|new[87]	ana|ana	13-1[0_87]|14-1
12-7	1659-1664	model	abstract[87]	new[87]	_	_
12-8	1665-1666	(	_	_	_	_
12-9	1667-1671	i.e.	object[90]	new[90]	_	_
12-10	1672-1673	,	object[90]	new[90]	_	_
12-11	1674-1691	chondroprogenitor	time|object[90]	new|new[90]	_	_
12-12	1692-1698	clonal	object[90]	new[90]	_	_
12-13	1699-1703	cell	object|object[90]	new|new[90]	_	_
12-14	1704-1708	line	object[90]	new[90]	_	_
12-15	1709-1710	)	_	_	_	_
12-16	1711-1714	the	substance[91]	new[91]	_	_
12-17	1715-1722	enzymes	substance[91]	new[91]	_	_
12-18	1723-1734	responsible	substance[91]	new[91]	_	_
12-19	1735-1738	for	substance[91]	new[91]	_	_
12-20	1739-1745	fibrin	substance[91]|substance|object[93]|event[94]	new[91]|giv|giv[93]|giv[94]	coref|coref	13-16|13-16[103_94]
12-21	1746-1749	gel	substance[91]|object[93]|event[94]	new[91]|giv[93]|giv[94]	_	_
12-22	1750-1759	breakdown	substance[91]|event[94]	new[91]|giv[94]	_	_
12-23	1760-1761	.	_	_	_	_

#Text=It appeared that metalloproteinases ( MMP-2 , MMP-3 , MMP-9 ) were secreted concomitantly with fibrin hydrogels breakdown .
13-1	1762-1764	It	abstract	giv	_	_
13-2	1765-1773	appeared	_	_	_	_
13-3	1774-1778	that	_	_	_	_
13-4	1779-1797	metalloproteinases	substance	giv	appos	13-6[98_0]
13-5	1798-1799	(	_	_	_	_
13-6	1800-1805	MMP-2	abstract|substance[98]	new|giv[98]	_	_
13-7	1806-1807	,	substance[98]	giv[98]	_	_
13-8	1808-1813	MMP-3	substance[98]|abstract	giv[98]|new	_	_
13-9	1814-1815	,	_	_	_	_
13-10	1816-1821	MMP-9	abstract	new	_	_
13-11	1822-1823	)	_	_	_	_
13-12	1824-1828	were	_	_	_	_
13-13	1829-1837	secreted	_	_	_	_
13-14	1838-1851	concomitantly	_	_	_	_
13-15	1852-1856	with	_	_	_	_
13-16	1857-1863	fibrin	substance|substance[102]|event[103]	giv|new[102]|giv[103]	coref|coref|coref	14-12[109_103]|15-16|15-16[116_102]
13-17	1864-1873	hydrogels	substance[102]|event[103]	new[102]|giv[103]	_	_
13-18	1874-1883	breakdown	event[103]	giv[103]	_	_
13-19	1884-1885	.	_	_	_	_

#Text=They also noted high plasmin activity in the conditioned media during hydrogel breakdown .
14-1	1886-1890	They	abstract	giv	ana	15-3
14-2	1891-1895	also	_	_	_	_
14-3	1896-1901	noted	_	_	_	_
14-4	1902-1906	high	abstract[106]	new[106]	coref	28-9[204_106]
14-5	1907-1914	plasmin	substance|abstract[106]	giv|new[106]	coref	27-8[189_0]
14-6	1915-1923	activity	abstract[106]	new[106]	_	_
14-7	1924-1926	in	abstract[106]	new[106]	_	_
14-8	1927-1930	the	abstract[106]|substance[107]	new[106]|new[107]	_	_
14-9	1931-1942	conditioned	abstract[106]|substance[107]	new[106]|new[107]	_	_
14-10	1943-1948	media	abstract[106]|substance[107]	new[106]|new[107]	_	_
14-11	1949-1955	during	_	_	_	_
14-12	1956-1964	hydrogel	substance|event[109]	new|giv[109]	_	_
14-13	1965-1974	breakdown	event[109]	giv[109]	_	_
14-14	1975-1976	.	_	_	_	_

#Text=Then , they demonstrated that aprotinin and galardin , in combination or separately , prevented fibrin hydrogels degradation .
15-1	1977-1981	Then	_	_	_	_
15-2	1982-1983	,	_	_	_	_
15-3	1984-1988	they	abstract	giv	coref	15-6[112_0]
15-4	1989-2001	demonstrated	_	_	_	_
15-5	2002-2006	that	_	_	_	_
15-6	2007-2016	aprotinin	person|abstract[112]	giv|giv[112]	_	_
15-7	2017-2020	and	abstract[112]	giv[112]	_	_
15-8	2021-2029	galardin	abstract[112]|plant[113]	giv[112]|giv[113]	_	_
15-9	2030-2031	,	abstract[112]|plant[113]	giv[112]|giv[113]	_	_
15-10	2032-2034	in	abstract[112]|plant[113]	giv[112]|giv[113]	_	_
15-11	2035-2046	combination	abstract[112]|plant[113]|abstract	giv[112]|giv[113]|new	coref	18-8[126_0]
15-12	2047-2049	or	_	_	_	_
15-13	2050-2060	separately	_	_	_	_
15-14	2061-2062	,	_	_	_	_
15-15	2063-2072	prevented	_	_	_	_
15-16	2073-2079	fibrin	substance|substance[116]|abstract[117]	giv|giv[116]|giv[117]	coref|coref	17-9|31-7[229_117]
15-17	2080-2089	hydrogels	substance[116]|abstract[117]	giv[116]|giv[117]	_	_
15-18	2090-2101	degradation	abstract[117]	giv[117]	_	_
15-19	2102-2103	.	_	_	_	_

#Text=Figure 4
16-1	2104-2110	Figure	abstract[118]	new[118]	coref	44-1[289_118]
16-2	2111-2112	4	abstract[118]	new[118]	_	_

#Text=summarizes the modifications which can be made on fibrin matrix to regulate the release of entrapped agents .
17-1	2113-2123	summarizes	_	_	_	_
17-2	2124-2127	the	abstract[119]	new[119]	coref	20-4[139_119]
17-3	2128-2141	modifications	abstract[119]	new[119]	_	_
17-4	2142-2147	which	abstract[119]	new[119]	_	_
17-5	2148-2151	can	abstract[119]	new[119]	_	_
17-6	2152-2154	be	abstract[119]	new[119]	_	_
17-7	2155-2159	made	abstract[119]	new[119]	_	_
17-8	2160-2162	on	abstract[119]	new[119]	_	_
17-9	2163-2169	fibrin	abstract[119]|substance|substance[121]	new[119]|giv|giv[121]	coref|coref	18-3|27-33[200_121]
17-10	2170-2176	matrix	abstract[119]|substance[121]	new[119]|giv[121]	_	_
17-11	2177-2179	to	_	_	_	_
17-12	2180-2188	regulate	_	_	_	_
17-13	2189-2192	the	event[122]	new[122]	_	_
17-14	2193-2200	release	event[122]	new[122]	_	_
17-15	2201-2203	of	event[122]	new[122]	_	_
17-16	2204-2213	entrapped	event[122]|person[123]	new[122]|new[123]	coref	18-5[125_123]
17-17	2214-2220	agents	event[122]|person[123]	new[122]|new[123]	_	_
17-18	2221-2222	.	_	_	_	_

#Text=5.2. Modifying Fibrin and/or Active Agents for Efficient Combination and Delivery
18-1	2223-2227	5.2.	_	_	_	_
18-2	2228-2237	Modifying	_	_	_	_
18-3	2238-2244	Fibrin	substance	giv	coref	19-5
18-4	2245-2251	and/or	_	_	_	_
18-5	2252-2258	Active	person[125]	giv[125]	_	_
18-6	2259-2265	Agents	person[125]	giv[125]	_	_
18-7	2266-2269	for	_	_	_	_
18-8	2270-2279	Efficient	abstract[126]	giv[126]	_	_
18-9	2280-2291	Combination	abstract[126]	giv[126]	_	_
18-10	2292-2295	and	_	_	_	_
18-11	2296-2304	Delivery	abstract	giv	coref	22-9

#Text=In some instances , fibrin exhibits innate affinity for therapeutics and growth factors but in other cases , the covalent attachment of these compounds to fibrin is considered .
19-1	2305-2307	In	_	_	_	_
19-2	2308-2312	some	person[128]	new[128]	_	_
19-3	2313-2322	instances	person[128]	new[128]	_	_
19-4	2323-2324	,	_	_	_	_
19-5	2325-2331	fibrin	substance	giv	coref	19-26
19-6	2332-2340	exhibits	_	_	_	_
19-7	2341-2347	innate	abstract[130]	giv[130]	_	_
19-8	2348-2356	affinity	abstract[130]	giv[130]	_	_
19-9	2357-2360	for	abstract[130]	giv[130]	_	_
19-10	2361-2373	therapeutics	abstract[130]|abstract	giv[130]|new	_	_
19-11	2374-2377	and	abstract[130]	giv[130]	_	_
19-12	2378-2384	growth	abstract[130]|abstract|abstract[133]	giv[130]|giv|giv[133]	coref|coref	22-12|22-12[154_133]
19-13	2385-2392	factors	abstract[130]|abstract[133]	giv[130]|giv[133]	_	_
19-14	2393-2396	but	_	_	_	_
19-15	2397-2399	in	_	_	_	_
19-16	2400-2405	other	abstract[134]	new[134]	_	_
19-17	2406-2411	cases	abstract[134]	new[134]	_	_
19-18	2412-2413	,	_	_	_	_
19-19	2414-2417	the	abstract[135]	new[135]	ana	20-1[0_135]
19-20	2418-2426	covalent	abstract[135]	new[135]	_	_
19-21	2427-2437	attachment	abstract[135]	new[135]	_	_
19-22	2438-2440	of	abstract[135]	new[135]	_	_
19-23	2441-2446	these	abstract[135]|substance[136]	new[135]|giv[136]	coref	37-5[253_136]
19-24	2447-2456	compounds	abstract[135]|substance[136]	new[135]|giv[136]	_	_
19-25	2457-2459	to	abstract[135]	new[135]	_	_
19-26	2460-2466	fibrin	abstract[135]|substance	new[135]|giv	coref	23-13
19-27	2467-2469	is	_	_	_	_
19-28	2470-2480	considered	_	_	_	_
19-29	2481-2482	.	_	_	_	_

#Text=This generally requires chemical modifications with reactive functional groups ( thiols , azides ) allowing a stable association .
20-1	2483-2487	This	abstract	giv	coref	26-20[185_0]
20-2	2488-2497	generally	_	_	_	_
20-3	2498-2506	requires	_	_	_	_
20-4	2507-2515	chemical	abstract[139]	giv[139]	coref	35-9[247_139]
20-5	2516-2529	modifications	abstract[139]	giv[139]	_	_
20-6	2530-2534	with	abstract[139]	giv[139]	_	_
20-7	2535-2543	reactive	abstract[139]|person[140]	giv[139]|giv[140]	coref	30-31[221_140]
20-8	2544-2554	functional	abstract[139]|person[140]	giv[139]|giv[140]	_	_
20-9	2555-2561	groups	abstract[139]|person[140]	giv[139]|giv[140]	_	_
20-10	2562-2563	(	_	_	_	_
20-11	2564-2570	thiols	substance	new	_	_
20-12	2571-2572	,	_	_	_	_
20-13	2573-2579	azides	substance	new	_	_
20-14	2580-2581	)	_	_	_	_
20-15	2582-2590	allowing	_	_	_	_
20-16	2591-2592	a	abstract[143]	new[143]	_	_
20-17	2593-2599	stable	abstract[143]	new[143]	_	_
20-18	2600-2611	association	abstract[143]	new[143]	_	_
20-19	2612-2613	.	_	_	_	_

#Text=Then , reduction/hydrolysis reactions or enzymatic cleavage mediate the release of active molecules .
21-1	2614-2618	Then	_	_	_	_
21-2	2619-2620	,	_	_	_	_
21-3	2621-2641	reduction/hydrolysis	event|event[145]	new|new[145]	_	_
21-4	2642-2651	reactions	event[145]	new[145]	_	_
21-5	2652-2654	or	_	_	_	_
21-6	2655-2664	enzymatic	event[146]	new[146]	coref	27-21[0_146]
21-7	2665-2673	cleavage	event[146]	new[146]	_	_
21-8	2674-2681	mediate	_	_	_	_
21-9	2682-2685	the	event[147]	new[147]	ana	22-1[0_147]
21-10	2686-2693	release	event[147]	new[147]	_	_
21-11	2694-2696	of	event[147]	new[147]	_	_
21-12	2697-2703	active	event[147]|object[148]	new[147]|giv[148]	coref	29-5[206_148]
21-13	2704-2713	molecules	event[147]|object[148]	new[147]|giv[148]	_	_
21-14	2714-2715	.	_	_	_	_

#Text=It was shown that this approach prolongs the delivery phase of growth factors for example .
22-1	2716-2718	It	event	giv	_	_
22-2	2719-2722	was	_	_	_	_
22-3	2723-2728	shown	_	_	_	_
22-4	2729-2733	that	_	_	_	_
22-5	2734-2738	this	abstract[150]	new[150]	_	_
22-6	2739-2747	approach	abstract[150]	new[150]	_	_
22-7	2748-2756	prolongs	_	_	_	_
22-8	2757-2760	the	abstract[152]	new[152]	_	_
22-9	2761-2769	delivery	abstract|abstract[152]	giv|new[152]	_	_
22-10	2770-2775	phase	abstract[152]	new[152]	_	_
22-11	2776-2778	of	abstract[152]	new[152]	_	_
22-12	2779-2785	growth	abstract[152]|abstract|abstract[154]	new[152]|giv|giv[154]	coref	27-30
22-13	2786-2793	factors	abstract[152]|abstract[154]	new[152]|giv[154]	_	_
22-14	2794-2797	for	_	_	_	_
22-15	2798-2805	example	_	_	_	_
22-16	2806-2807	.	_	_	_	_

#Text=As another illustration , covalently binding of BMP and RGD sequences to fibrin allows interactions with bone marrow stromal cells through integrin surface receptors that triggered downstream signaling pathways .
23-1	2808-2810	As	_	_	_	_
23-2	2811-2818	another	object[155]	new[155]	_	_
23-3	2819-2831	illustration	object[155]	new[155]	_	_
23-4	2832-2833	,	_	_	_	_
23-5	2834-2844	covalently	object[156]	new[156]	coref	36-3[248_156]
23-6	2845-2852	binding	object[156]	new[156]	_	_
23-7	2853-2855	of	object[156]	new[156]	_	_
23-8	2856-2859	BMP	object[156]|object|abstract[159]	new[156]|new|new[159]	coref	30-6
23-9	2860-2863	and	object[156]|abstract[159]	new[156]|new[159]	_	_
23-10	2864-2867	RGD	object[156]|abstract|abstract[159]	new[156]|new|new[159]	_	_
23-11	2868-2877	sequences	object[156]|abstract[159]	new[156]|new[159]	_	_
23-12	2878-2880	to	object[156]	new[156]	_	_
23-13	2881-2887	fibrin	object[156]|substance	new[156]|giv	coref	26-24
23-14	2888-2894	allows	_	_	_	_
23-15	2895-2907	interactions	event[161]	new[161]	coref	30-24[218_161]
23-16	2908-2912	with	event[161]	new[161]	_	_
23-17	2913-2917	bone	event[161]|object|animal[163]|animal[165]	new[161]|new|new[163]|new[165]	_	_
23-18	2918-2924	marrow	event[161]|animal[163]|animal[165]	new[161]|new[163]|new[165]	_	_
23-19	2925-2932	stromal	event[161]|animal|animal[165]	new[161]|new|new[165]	_	_
23-20	2933-2938	cells	event[161]|animal[165]	new[161]|new[165]	_	_
23-21	2939-2946	through	_	_	_	_
23-22	2947-2955	integrin	person|abstract[168]	new|new[168]	_	_
23-23	2956-2963	surface	place|abstract[168]	new|new[168]	coref	41-16
23-24	2964-2973	receptors	abstract[168]	new[168]	_	_
23-25	2974-2978	that	abstract[168]	new[168]	_	_
23-26	2979-2988	triggered	abstract[168]	new[168]	_	_
23-27	2989-2999	downstream	abstract[168]|abstract[170]	new[168]|new[170]	_	_
23-28	3000-3009	signaling	abstract[168]|abstract|abstract[170]	new[168]|new|new[170]	_	_
23-29	3010-3018	pathways	abstract[168]|abstract[170]	new[168]|new[170]	_	_
23-30	3019-3020	.	_	_	_	_

#Text=More sophisticated constructions have been tested .
24-1	3021-3025	More	abstract[171]	new[171]	_	_
24-2	3026-3039	sophisticated	abstract[171]	new[171]	_	_
24-3	3040-3053	constructions	abstract[171]	new[171]	_	_
24-4	3054-3058	have	_	_	_	_
24-5	3059-3063	been	_	_	_	_
24-6	3064-3070	tested	_	_	_	_
24-7	3071-3072	.	_	_	_	_

#Text=Starting from BMP-2 , Schmoekel et al. propose a tripartite fusion protein denoted as TG-pl-BMP-2 .
25-1	3073-3081	Starting	_	_	_	_
25-2	3082-3086	from	_	_	_	_
25-3	3087-3092	BMP-2	abstract	new	coref	28-6
25-4	3093-3094	,	_	_	_	_
25-5	3095-3104	Schmoekel	person	new	_	_
25-6	3105-3107	et	_	_	_	_
25-7	3108-3111	al.	_	_	_	_
25-8	3112-3119	propose	_	_	_	_
25-9	3120-3121	a	substance[175]	new[175]	_	_
25-10	3122-3132	tripartite	substance[175]	new[175]	_	_
25-11	3133-3139	fusion	abstract|substance[175]	new|new[175]	_	_
25-12	3140-3147	protein	substance[175]	new[175]	_	_
25-13	3148-3155	denoted	substance[175]	new[175]	_	_
25-14	3156-3158	as	substance[175]	new[175]	_	_
25-15	3159-3170	TG-pl-BMP-2	substance[175]|abstract	new[175]|new	_	_
25-16	3171-3172	.	_	_	_	_

#Text=Under the control of the blood transglutaminase factor XIIIa , the N-terminal transglutaminase substrate domain ( TG ) provides a covalent attachment to fibrin during coagulation .
26-1	3173-3178	Under	_	_	_	_
26-2	3179-3182	the	abstract[177]	new[177]	_	_
26-3	3183-3190	control	abstract[177]	new[177]	_	_
26-4	3191-3193	of	abstract[177]	new[177]	_	_
26-5	3194-3197	the	abstract[177]|abstract[180]	new[177]|new[180]	coref	27-28[198_180]
26-6	3198-3203	blood	abstract[177]|substance|abstract[179]|abstract[180]	new[177]|new|new[179]|new[180]	coref	26-13[0_179]
26-7	3204-3220	transglutaminase	abstract[177]|abstract[179]|abstract[180]	new[177]|new[179]|new[180]	_	_
26-8	3221-3227	factor	abstract[177]|abstract[180]	new[177]|new[180]	_	_
26-9	3228-3233	XIIIa	abstract[177]|abstract[180]	new[177]|new[180]	_	_
26-10	3234-3235	,	_	_	_	_
26-11	3236-3239	the	abstract[183]	new[183]	appos	26-17[0_183]
26-12	3240-3250	N-terminal	abstract[183]	new[183]	_	_
26-13	3251-3267	transglutaminase	abstract|abstract[183]	giv|new[183]	_	_
26-14	3268-3277	substrate	person|abstract[183]	new|new[183]	coref	27-14
26-15	3278-3284	domain	abstract[183]	new[183]	_	_
26-16	3285-3286	(	_	_	_	_
26-17	3287-3289	TG	abstract	giv	coref	27-11[192_0]
26-18	3290-3291	)	_	_	_	_
26-19	3292-3300	provides	_	_	_	_
26-20	3301-3302	a	abstract[185]	giv[185]	_	_
26-21	3303-3311	covalent	abstract[185]	giv[185]	_	_
26-22	3312-3322	attachment	abstract[185]	giv[185]	_	_
26-23	3323-3325	to	abstract[185]	giv[185]	_	_
26-24	3326-3332	fibrin	abstract[185]|substance	giv[185]|giv	coref	27-34
26-25	3333-3339	during	_	_	_	_
26-26	3340-3351	coagulation	event	new	_	_
26-27	3352-3353	.	_	_	_	_

#Text=In addition , upon the action of cell-activated plasmin , the central plasmin substrate domain ( pl ) gives a cleavage site for the local release of the attached growth factor from the fibrin matrix .
27-1	3354-3356	In	_	_	_	_
27-2	3357-3365	addition	_	_	_	_
27-3	3366-3367	,	_	_	_	_
27-4	3368-3372	upon	_	_	_	_
27-5	3373-3376	the	event[188]	new[188]	_	_
27-6	3377-3383	action	event[188]	new[188]	_	_
27-7	3384-3386	of	event[188]	new[188]	_	_
27-8	3387-3401	cell-activated	event[188]|substance[189]	new[188]|giv[189]	coref	27-13[0_189]
27-9	3402-3409	plasmin	event[188]|substance[189]	new[188]|giv[189]	_	_
27-10	3410-3411	,	_	_	_	_
27-11	3412-3415	the	abstract[192]	giv[192]	appos	27-17[0_192]
27-12	3416-3423	central	abstract[192]	giv[192]	_	_
27-13	3424-3431	plasmin	substance|abstract[192]	giv|giv[192]	_	_
27-14	3432-3441	substrate	person|abstract[192]	giv|giv[192]	_	_
27-15	3442-3448	domain	abstract[192]	giv[192]	_	_
27-16	3449-3450	(	_	_	_	_
27-17	3451-3453	pl	abstract	giv	coref	28-3[203_0]
27-18	3454-3455	)	_	_	_	_
27-19	3456-3461	gives	_	_	_	_
27-20	3462-3463	a	place[195]	new[195]	_	_
27-21	3464-3472	cleavage	event|place[195]	giv|new[195]	_	_
27-22	3473-3477	site	place[195]	new[195]	_	_
27-23	3478-3481	for	place[195]	new[195]	_	_
27-24	3482-3485	the	place[195]|event[196]	new[195]|new[196]	_	_
27-25	3486-3491	local	place[195]|event[196]	new[195]|new[196]	_	_
27-26	3492-3499	release	place[195]|event[196]	new[195]|new[196]	_	_
27-27	3500-3502	of	place[195]|event[196]	new[195]|new[196]	_	_
27-28	3503-3506	the	place[195]|event[196]|abstract[198]	new[195]|new[196]|giv[198]	_	_
27-29	3507-3515	attached	place[195]|event[196]|abstract[198]	new[195]|new[196]|giv[198]	_	_
27-30	3516-3522	growth	place[195]|event[196]|abstract|abstract[198]	new[195]|new[196]|giv|giv[198]	coref	33-15
27-31	3523-3529	factor	place[195]|event[196]|abstract[198]	new[195]|new[196]|giv[198]	_	_
27-32	3530-3534	from	place[195]|event[196]|abstract[198]	new[195]|new[196]|giv[198]	_	_
27-33	3535-3538	the	place[195]|event[196]|abstract[198]|substance[200]	new[195]|new[196]|giv[198]|giv[200]	coref	30-9[213_200]
27-34	3539-3545	fibrin	place[195]|event[196]|abstract[198]|substance|substance[200]	new[195]|new[196]|giv[198]|giv|giv[200]	coref	29-9
27-35	3546-3552	matrix	place[195]|event[196]|abstract[198]|substance[200]	new[195]|new[196]|giv[198]|giv[200]	_	_
27-36	3553-3554	.	_	_	_	_

#Text=Lastly , the C-terminal human BMP-2 domain displays an osteogenic activity .
28-1	3555-3561	Lastly	_	_	_	_
28-2	3562-3563	,	_	_	_	_
28-3	3564-3567	the	abstract[203]	giv[203]	_	_
28-4	3568-3578	C-terminal	place|abstract[203]	new|giv[203]	_	_
28-5	3579-3584	human	abstract[203]	giv[203]	_	_
28-6	3585-3590	BMP-2	abstract|abstract[203]	giv|giv[203]	_	_
28-7	3591-3597	domain	abstract[203]	giv[203]	_	_
28-8	3598-3606	displays	_	_	_	_
28-9	3607-3609	an	abstract[204]	giv[204]	_	_
28-10	3610-3620	osteogenic	abstract[204]	giv[204]	_	_
28-11	3621-3629	activity	abstract[204]	giv[204]	_	_
28-12	3630-3631	.	_	_	_	_

#Text=As an alternative to active molecules derivatization , fibrin functionalization can also be achieved .
29-1	3632-3634	As	_	_	_	_
29-2	3635-3637	an	abstract[205]	new[205]	coref	37-2[252_205]
29-3	3638-3649	alternative	abstract[205]	new[205]	_	_
29-4	3650-3652	to	abstract[205]	new[205]	_	_
29-5	3653-3659	active	abstract[205]|object[206]|abstract[207]	new[205]|giv[206]|new[207]	_	_
29-6	3660-3669	molecules	abstract[205]|object[206]|abstract[207]	new[205]|giv[206]|new[207]	_	_
29-7	3670-3684	derivatization	abstract[205]|abstract[207]	new[205]|new[207]	_	_
29-8	3685-3686	,	_	_	_	_
29-9	3687-3693	fibrin	substance|abstract[209]	giv|new[209]	coref|coref	30-10|33-15[240_209]
29-10	3694-3711	functionalization	abstract[209]	new[209]	_	_
29-11	3712-3715	can	_	_	_	_
29-12	3716-3720	also	_	_	_	_
29-13	3721-3723	be	_	_	_	_
29-14	3724-3732	achieved	_	_	_	_
29-15	3733-3734	.	_	_	_	_

#Text=For example , to facilitate BMP interaction with a fibrin matrix , Yang et al. grafted heparin onto fibrin , this leading to electrostatic interactions between the negative charges of heparin sulfate groups , and the positive charges of BMPs amino acid residues .
30-1	3735-3738	For	_	_	_	_
30-2	3739-3746	example	_	_	_	_
30-3	3747-3748	,	_	_	_	_
30-4	3749-3751	to	_	_	_	_
30-5	3752-3762	facilitate	_	_	_	_
30-6	3763-3766	BMP	object|event[211]	giv|new[211]	_	_
30-7	3767-3778	interaction	event[211]	new[211]	_	_
30-8	3779-3783	with	event[211]	new[211]	_	_
30-9	3784-3785	a	event[211]|substance[213]	new[211]|giv[213]	ana	30-21[0_213]
30-10	3786-3792	fibrin	event[211]|substance|substance[213]	new[211]|giv|giv[213]	coref	30-19
30-11	3793-3799	matrix	event[211]|substance[213]	new[211]|giv[213]	_	_
30-12	3800-3801	,	_	_	_	_
30-13	3802-3806	Yang	person	new	_	_
30-14	3807-3809	et	_	_	_	_
30-15	3810-3813	al.	_	_	_	_
30-16	3814-3821	grafted	_	_	_	_
30-17	3822-3829	heparin	animal	new	coref	31-3
30-18	3830-3834	onto	_	_	_	_
30-19	3835-3841	fibrin	substance	giv	coref	31-7
30-20	3842-3843	,	_	_	_	_
30-21	3844-3848	this	substance	giv	_	_
30-22	3849-3856	leading	_	_	_	_
30-23	3857-3859	to	_	_	_	_
30-24	3860-3873	electrostatic	event[218]	giv[218]	_	_
30-25	3874-3886	interactions	event[218]	giv[218]	_	_
30-26	3887-3894	between	event[218]	giv[218]	_	_
30-27	3895-3898	the	event[218]|abstract[219]	giv[218]|new[219]	_	_
30-28	3899-3907	negative	event[218]|abstract[219]	giv[218]|new[219]	_	_
30-29	3908-3915	charges	event[218]|abstract[219]	giv[218]|new[219]	_	_
30-30	3916-3918	of	event[218]|abstract[219]	giv[218]|new[219]	_	_
30-31	3919-3926	heparin	event[218]|abstract[219]|person[221]	giv[218]|new[219]|giv[221]	ana	39-1[0_221]
30-32	3927-3934	sulfate	event[218]|abstract[219]|substance|person[221]	giv[218]|new[219]|new|giv[221]	_	_
30-33	3935-3941	groups	event[218]|abstract[219]|person[221]	giv[218]|new[219]|giv[221]	_	_
30-34	3942-3943	,	event[218]	giv[218]	_	_
30-35	3944-3947	and	event[218]	giv[218]	_	_
30-36	3948-3951	the	event[218]|abstract[222]	giv[218]|new[222]	_	_
30-37	3952-3960	positive	event[218]|abstract[222]	giv[218]|new[222]	_	_
30-38	3961-3968	charges	event[218]|abstract[222]	giv[218]|new[222]	_	_
30-39	3969-3971	of	event[218]|abstract[222]	giv[218]|new[222]	_	_
30-40	3972-3976	BMPs	event[218]|abstract[222]|object|substance[224]|object[225]	giv[218]|new[222]|new|new[224]|new[225]	coref	31-15[231_0]
30-41	3977-3982	amino	event[218]|abstract[222]|substance[224]|object[225]	giv[218]|new[222]|new[224]|new[225]	_	_
30-42	3983-3987	acid	event[218]|abstract[222]|substance[224]|object[225]	giv[218]|new[222]|new[224]|new[225]	_	_
30-43	3988-3996	residues	event[218]|abstract[222]|object[225]	giv[218]|new[222]|new[225]	_	_
30-44	3997-3998	.	_	_	_	_

#Text=Interestingly , heparin presence slowed down fibrin degradation , and consequently the release of loaded BMPs .
31-1	3999-4012	Interestingly	_	_	_	_
31-2	4013-4014	,	_	_	_	_
31-3	4015-4022	heparin	animal|abstract[227]	giv|new[227]	_	_
31-4	4023-4031	presence	abstract[227]	new[227]	_	_
31-5	4032-4038	slowed	_	_	_	_
31-6	4039-4043	down	_	_	_	_
31-7	4044-4050	fibrin	substance|abstract[229]	giv|giv[229]	coref	33-13
31-8	4051-4062	degradation	abstract[229]	giv[229]	_	_
31-9	4063-4064	,	_	_	_	_
31-10	4065-4068	and	_	_	_	_
31-11	4069-4081	consequently	event[230]	new[230]	coref	37-16[256_230]
31-12	4082-4085	the	event[230]	new[230]	_	_
31-13	4086-4093	release	event[230]	new[230]	_	_
31-14	4094-4096	of	event[230]	new[230]	_	_
31-15	4097-4103	loaded	event[230]|object[231]	new[230]|giv[231]	_	_
31-16	4104-4108	BMPs	event[230]|object[231]	new[230]|giv[231]	_	_
31-17	4109-4110	.	_	_	_	_

#Text=Similar observations were made with FGF .
32-1	4111-4118	Similar	abstract[232]	new[232]	_	_
32-2	4119-4131	observations	abstract[232]	new[232]	_	_
32-3	4132-4136	were	_	_	_	_
32-4	4137-4141	made	_	_	_	_
32-5	4142-4146	with	_	_	_	_
32-6	4147-4150	FGF	abstract	giv	_	_
32-7	4151-4152	.	_	_	_	_

#Text=Despite positive effects reported in literature , there are several drawbacks to fibrin or growth factors/proteins functionalization .
33-1	4153-4160	Despite	_	_	_	_
33-2	4161-4169	positive	abstract[234]	new[234]	_	_
33-3	4170-4177	effects	abstract[234]	new[234]	_	_
33-4	4178-4186	reported	abstract[234]	new[234]	_	_
33-5	4187-4189	in	abstract[234]	new[234]	_	_
33-6	4190-4200	literature	abstract[234]|abstract	new[234]|new	_	_
33-7	4201-4202	,	_	_	_	_
33-8	4203-4208	there	_	_	_	_
33-9	4209-4212	are	_	_	_	_
33-10	4213-4220	several	abstract[236]	new[236]	_	_
33-11	4221-4230	drawbacks	abstract[236]	new[236]	_	_
33-12	4231-4233	to	abstract[236]	new[236]	_	_
33-13	4234-4240	fibrin	abstract[236]|substance	new[236]|giv	coref	40-8
33-14	4241-4243	or	abstract[236]	new[236]	_	_
33-15	4244-4250	growth	abstract[236]|abstract|abstract[240]	new[236]|giv|giv[240]	ana	34-5[0_240]
33-16	4251-4267	factors/proteins	abstract[236]|substance|abstract[240]	new[236]|new|giv[240]	_	_
33-17	4268-4285	functionalization	abstract[236]|abstract[240]	new[236]|giv[240]	_	_
33-18	4286-4287	.	_	_	_	_

#Text=First of all , it requires specific skills , and it is time consuming and expensive .
34-1	4288-4293	First	_	_	_	_
34-2	4294-4296	of	_	_	_	_
34-3	4297-4300	all	_	_	_	_
34-4	4301-4302	,	_	_	_	_
34-5	4303-4305	it	abstract	giv	ana	34-11
34-6	4306-4314	requires	_	_	_	_
34-7	4315-4323	specific	abstract[242]	new[242]	_	_
34-8	4324-4330	skills	abstract[242]	new[242]	_	_
34-9	4331-4332	,	_	_	_	_
34-10	4333-4336	and	_	_	_	_
34-11	4337-4339	it	abstract	giv	_	_
34-12	4340-4342	is	_	_	_	_
34-13	4343-4347	time	time	new	_	_
34-14	4348-4357	consuming	_	_	_	_
34-15	4358-4361	and	_	_	_	_
34-16	4362-4371	expensive	_	_	_	_
34-17	4372-4373	.	_	_	_	_

#Text=Furthermore , proteins functionality can be altered by these modifications .
35-1	4374-4385	Furthermore	_	_	_	_
35-2	4386-4387	,	_	_	_	_
35-3	4388-4396	proteins	substance|abstract[246]	new|new[246]	_	_
35-4	4397-4410	functionality	abstract[246]	new[246]	_	_
35-5	4411-4414	can	_	_	_	_
35-6	4415-4417	be	_	_	_	_
35-7	4418-4425	altered	_	_	_	_
35-8	4426-4428	by	_	_	_	_
35-9	4429-4434	these	abstract[247]	giv[247]	coref	43-1[288_247]
35-10	4435-4448	modifications	abstract[247]	giv[247]	_	_
35-11	4449-4450	.	_	_	_	_

#Text=Indeed , covalent binding can mask active sites , thus affecting their bioactivity .
36-1	4451-4457	Indeed	_	_	_	_
36-2	4458-4459	,	_	_	_	_
36-3	4460-4468	covalent	object[248]	giv[248]	_	_
36-4	4469-4476	binding	object[248]	giv[248]	_	_
36-5	4477-4480	can	_	_	_	_
36-6	4481-4485	mask	_	_	_	_
36-7	4486-4492	active	place[249]	new[249]	ana	36-12[0_249]
36-8	4493-4498	sites	place[249]	new[249]	_	_
36-9	4499-4500	,	_	_	_	_
36-10	4501-4505	thus	_	_	_	_
36-11	4506-4515	affecting	_	_	_	_
36-12	4516-4521	their	place|abstract[251]	giv|new[251]	coref	42-11[287_251]
36-13	4522-4533	bioactivity	abstract[251]	new[251]	_	_
36-14	4534-4535	.	_	_	_	_

#Text=As an alternative , non-modified compounds can be internalized into particles , to slow down their release .
37-1	4536-4538	As	_	_	_	_
37-2	4539-4541	an	abstract[252]	giv[252]	_	_
37-3	4542-4553	alternative	abstract[252]	giv[252]	_	_
37-4	4554-4555	,	_	_	_	_
37-5	4556-4568	non-modified	substance[253]	giv[253]	ana	37-16[0_253]
37-6	4569-4578	compounds	substance[253]	giv[253]	_	_
37-7	4579-4582	can	_	_	_	_
37-8	4583-4585	be	_	_	_	_
37-9	4586-4598	internalized	_	_	_	_
37-10	4599-4603	into	_	_	_	_
37-11	4604-4613	particles	object	new	_	_
37-12	4614-4615	,	_	_	_	_
37-13	4616-4618	to	_	_	_	_
37-14	4619-4623	slow	_	_	_	_
37-15	4624-4628	down	_	_	_	_
37-16	4629-4634	their	substance|event[256]	giv|giv[256]	coref	41-6[271_256]
37-17	4635-4642	release	event[256]	giv[256]	_	_
37-18	4643-4644	.	_	_	_	_

#Text=Wang et al. developed a sophisticated system which could serve to deliver low-molecular weight hydrophilic drugs .
38-1	4645-4649	Wang	person	new	_	_
38-2	4650-4652	et	_	_	_	_
38-3	4653-4656	al.	_	_	_	_
38-4	4657-4666	developed	_	_	_	_
38-5	4667-4668	a	abstract[258]	new[258]	_	_
38-6	4669-4682	sophisticated	abstract[258]	new[258]	_	_
38-7	4683-4689	system	abstract[258]	new[258]	_	_
38-8	4690-4695	which	abstract[258]	new[258]	_	_
38-9	4696-4701	could	abstract[258]	new[258]	_	_
38-10	4702-4707	serve	abstract[258]	new[258]	_	_
38-11	4708-4710	to	abstract[258]	new[258]	_	_
38-12	4711-4718	deliver	abstract[258]	new[258]	_	_
38-13	4719-4732	low-molecular	abstract[258]|abstract[259]|substance[260]	new[258]|new[259]|new[260]	_	_
38-14	4733-4739	weight	abstract[258]|abstract[259]|substance[260]	new[258]|new[259]|new[260]	_	_
38-15	4740-4751	hydrophilic	abstract[258]|substance[260]	new[258]|new[260]	_	_
38-16	4752-4757	drugs	abstract[258]|substance[260]	new[258]|new[260]	_	_
38-17	4758-4759	.	_	_	_	_

#Text=They used an antithrombosis drug ( i.e. , Tirofiban® ) as a drug model .
39-1	4760-4764	They	person	giv	_	_
39-2	4765-4769	used	_	_	_	_
39-3	4770-4772	an	substance[262]	new[262]	coref	39-13[0_262]
39-4	4773-4787	antithrombosis	substance[262]	new[262]	_	_
39-5	4788-4792	drug	substance[262]	new[262]	_	_
39-6	4793-4794	(	_	_	_	_
39-7	4795-4799	i.e.	abstract[263]	new[263]	_	_
39-8	4800-4801	,	abstract[263]	new[263]	_	_
39-9	4802-4812	Tirofiban®	abstract[263]	new[263]	_	_
39-10	4813-4814	)	_	_	_	_
39-11	4815-4817	as	_	_	_	_
39-12	4818-4819	a	abstract[265]	new[265]	_	_
39-13	4820-4824	drug	substance|abstract[265]	giv|new[265]	coref	41-6
39-14	4825-4830	model	abstract[265]	new[265]	_	_
39-15	4831-4832	.	_	_	_	_

#Text=Drug-loaded liposomes were first encapsulated in a fibrin gel , and then combined to chitosan .
40-1	4833-4844	Drug-loaded	substance[266]	new[266]	coref	41-19[0_266]
40-2	4845-4854	liposomes	substance[266]	new[266]	_	_
40-3	4855-4859	were	_	_	_	_
40-4	4860-4865	first	_	_	_	_
40-5	4866-4878	encapsulated	_	_	_	_
40-6	4879-4881	in	_	_	_	_
40-7	4882-4883	a	substance[268]	new[268]	_	_
40-8	4884-4890	fibrin	substance|substance[268]	giv|new[268]	coref	41-33
40-9	4891-4894	gel	substance[268]	new[268]	_	_
40-10	4895-4896	,	_	_	_	_
40-11	4897-4900	and	_	_	_	_
40-12	4901-4905	then	_	_	_	_
40-13	4906-4914	combined	_	_	_	_
40-14	4915-4917	to	_	_	_	_
40-15	4918-4926	chitosan	substance	new	coref	41-25
40-16	4927-4928	.	_	_	_	_

#Text=To document/characterize the in vitro drug release profile , different parameters were studied including the surface charge of liposomes , the pore size of chitosan structure , and the crosslinking degree of fibrin gels .
41-1	4929-4931	To	_	_	_	_
41-2	4932-4953	document/characterize	_	_	_	_
41-3	4954-4957	the	abstract[272]	new[272]	_	_
41-4	4958-4960	in	abstract[272]	new[272]	_	_
41-5	4961-4966	vitro	abstract[272]	new[272]	_	_
41-6	4967-4971	drug	substance|event[271]|abstract[272]	giv|giv[271]|new[272]	_	_
41-7	4972-4979	release	event[271]|abstract[272]	giv[271]|new[272]	_	_
41-8	4980-4987	profile	abstract[272]	new[272]	_	_
41-9	4988-4989	,	_	_	_	_
41-10	4990-4999	different	abstract[273]	new[273]	_	_
41-11	5000-5010	parameters	abstract[273]	new[273]	_	_
41-12	5011-5015	were	_	_	_	_
41-13	5016-5023	studied	_	_	_	_
41-14	5024-5033	including	_	_	_	_
41-15	5034-5037	the	abstract[275]	new[275]	_	_
41-16	5038-5045	surface	place|abstract[275]	giv|new[275]	_	_
41-17	5046-5052	charge	abstract[275]	new[275]	_	_
41-18	5053-5055	of	abstract[275]	new[275]	_	_
41-19	5056-5065	liposomes	abstract[275]|substance	new[275]|giv	_	_
41-20	5066-5067	,	_	_	_	_
41-21	5068-5071	the	abstract[278]	new[278]	_	_
41-22	5072-5076	pore	abstract|abstract[278]	new|new[278]	_	_
41-23	5077-5081	size	abstract[278]	new[278]	_	_
41-24	5082-5084	of	abstract[278]	new[278]	_	_
41-25	5085-5093	chitosan	abstract[278]|substance|abstract[280]	new[278]|giv|new[280]	_	_
41-26	5094-5103	structure	abstract[278]|abstract[280]	new[278]|new[280]	_	_
41-27	5104-5105	,	_	_	_	_
41-28	5106-5109	and	_	_	_	_
41-29	5110-5113	the	abstract[282]	new[282]	_	_
41-30	5114-5126	crosslinking	abstract|abstract[282]	new|new[282]	_	_
41-31	5127-5133	degree	abstract[282]	new[282]	_	_
41-32	5134-5136	of	abstract[282]	new[282]	_	_
41-33	5137-5143	fibrin	abstract[282]|substance|substance[284]	new[282]|giv|new[284]	_	_
41-34	5144-5148	gels	abstract[282]|substance[284]	new[282]|new[284]	_	_
41-35	5149-5150	.	_	_	_	_

#Text=All these experimental conditions offered different prolonged releases without altering the composite bioactivity .
42-1	5151-5154	All	abstract[285]	new[285]	_	_
42-2	5155-5160	these	abstract[285]	new[285]	_	_
42-3	5161-5173	experimental	abstract[285]	new[285]	_	_
42-4	5174-5184	conditions	abstract[285]	new[285]	_	_
42-5	5185-5192	offered	_	_	_	_
42-6	5193-5202	different	event[286]	new[286]	_	_
42-7	5203-5212	prolonged	event[286]	new[286]	_	_
42-8	5213-5221	releases	event[286]	new[286]	_	_
42-9	5222-5229	without	_	_	_	_
42-10	5230-5238	altering	_	_	_	_
42-11	5239-5242	the	abstract[287]	giv[287]	_	_
42-12	5243-5252	composite	abstract[287]	giv[287]	_	_
42-13	5253-5264	bioactivity	abstract[287]	giv[287]	_	_
42-14	5265-5266	.	_	_	_	_

#Text=All these modifications are summarized in
43-1	5267-5270	All	abstract[288]	giv[288]	_	_
43-2	5271-5276	these	abstract[288]	giv[288]	_	_
43-3	5277-5290	modifications	abstract[288]	giv[288]	_	_
43-4	5291-5294	are	_	_	_	_
43-5	5295-5305	summarized	_	_	_	_
43-6	5306-5308	in	_	_	_	_

#Text=Figure 4
44-1	5309-5315	Figure	abstract[289]	giv[289]	_	_
44-2	5316-5317	4	abstract[289]	giv[289]	_	_

#Text=.
45-1	5318-5319	.	_	_	_	_
